CA Patent

CA3145456A1 — Methods for administering (r)-n-[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamide

Assigned to Orion Oyj · Expires 2021-01-07 · 5y expired

What this patent protects

The invention relates to ocular, intranasal, oromucosal or pulmonary administration of (R)-N-[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamide (I) for the treatment of diseases and conditions where, for example, inotropic, vasodilatory or calcium sensitizing effects are…

USPTO Abstract

The invention relates to ocular, intranasal, oromucosal or pulmonary administration of (R)-N-[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamide (I) for the treatment of diseases and conditions where, for example, inotropic, vasodilatory or calcium sensitizing effects are desired. The invention also relates to pharmaceutical dosage forms adapted for ocular, intranasal, oromucosal or pulmonary administration comprising (R)-N-[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamide (I) as an active ingredient.

Drugs covered by this patent

Patent Metadata

Patent number
CA3145456A1
Jurisdiction
CA
Classification
—
Expires
2021-01-07
Drug substance claim
No
Drug product claim
No
Assignee
Orion Oyj
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.